FDA Approves Outlook Therapeutics’ Lytenava for Wet Age-Related Macular Degeneration

Marco Zingaro North America Legal Chronicle
Tagged:

Hogan Lovells Cadwalader has advised Outlook Therapeutics, Inc. Outlook Therapeutics, Inc. has obtained U.S. Food and Drug Administration (FDA) approval for LYTENAVA™ (bevacizumab-vikg), marking the company’s…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Marco Zingaro

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here